Anatoly Dritschilo - Aug 29, 2022 Form 3/A - Amendment Insider Report for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Role: CEO and Chairman, Director, 10%+ Owner
Signature: /s/ Anatoly Dritschilo
Stock symbol: SHPH
Transactions as of: Aug 29, 2022
Transactions value $: $0
Form type: 3/A - Amendment
Date filed: 9/8/2022, 09:11 AM
Date Of Original Report: Sep 7, 2022
Next filing: Jan 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SHPH	COMMON STOCK						1.09M	Aug 29, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3 amendment is being filed to correct the original Form 3 filed on September 7, 2022 as Table I, Line 1, had incorrectly listed the number of the Reporting Person's direct beneficial ownership; however, the footnote to the original Form 3 - reproduced below - correctly broke down the Reporting Person's direct beneficial ownership. In accordance with the instructions to Form 3, the lines which were properly reported in Table I of the original Form 3 are not being repeated in this Form 3/A.
F2	The undersigned became a Reporting Person subject to Section 16 reporting on August 29, 2022 at the time Shuttle Pharmaceuticals Holdings, Inc (the "Company") completed its initial public offering ("IPO"). At the time of the IPO, the Reporting Person was the beneficial owner of 1,093,572 shares of common stock of the Company, consisting of (i) 1,070,824 shares of common stock, and (ii) 22,748 restricted stock units ("RSUs"), of which 15,165 RSUs have fully vested and 7,583 remain subject to vesting.

Content

This Form 3 amendment is being filed to correct the original Form 3 filed on September 7, 2022 as Table I, Line 1, had incorrectly listed the number of the Reporting Person's direct beneficial ownership; however, the footnote to the original Form 3 - reproduced below - correctly broke down the Reporting Person's direct beneficial ownership. In accordance with the instructions to Form 3, the lines which were properly reported in Table I of the original Form 3 are not being repeated in this Form 3/A.

The undersigned became a Reporting Person subject to Section 16 reporting on August 29, 2022 at the time Shuttle Pharmaceuticals Holdings, Inc (the "Company") completed its initial public offering ("IPO"). At the time of the IPO, the Reporting Person was the beneficial owner of 1,093,572 shares of common stock of the Company, consisting of (i) 1,070,824 shares of common stock, and (ii) 22,748 restricted stock units ("RSUs"), of which 15,165 RSUs have fully vested and 7,583 remain subject to vesting.